These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23047244)

  • 1. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.
    Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
    Biol Pharm Bull; 2012; 35(12):2112-8. PubMed ID: 23047244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
    Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
    Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats.
    Akagi Y; Nio Y; Shimada S; Aoyama T
    Biol Pharm Bull; 2011; 34(2):233-7. PubMed ID: 21415533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
    Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
    Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
    Hong Y; Gengo FM; Rainka MM; Bates VE; Mager DE
    Clin Pharmacokinet; 2008; 47(2):129-37. PubMed ID: 18193919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
    Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
    N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model.
    Awa K; Satoh H; Hori S; Sawada Y
    J Clin Pharm Ther; 2012 Aug; 37(4):469-74. PubMed ID: 22122406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.